Immunohistochemical (IHC) Tumor Markers: Core Applications in Lung Cancer Diagnosis and Research

Key Concepts of IHC Tumor Markers

Tumor markers represent indispensable molecular indicators for early cancer screening, differential diagnosis, and prognostic evaluation in clinical oncology. As a gold-standard detection technique, immunohistochemistry (IHC) enables precise localization and quantitative analysis of target biomarkers in tissue samples, bridging molecular biology and clinical pathological diagnosis.

Research Frontiers and Clinical Significance

In contemporary oncology research, IHC-based biomarker analysis has become a cornerstone of precision medicine. By integrating IHC visualization results with clinical imaging data, clinicians can accurately determine tumor staging, biological behavior, and invasiveness, laying a solid foundation for individualized treatment strategy formulation.

For lung cancer, one of the most prevalent malignancies globally, specific IHC tumor markers are critical for early identification, subtype classification, and therapeutic response prediction, directly improving clinical management and patient outcomes.

Molecular Mechanisms and Core Biomarkers in Lung Cancer

1. c-Met (HGFR)

c-Met, a tyrosine-protein kinase encoded by the MET gene, functions as the hepatocyte growth factor receptor. Abnormal activation and dysregulation of the c-Met signaling pathway are closely associated with tumor proliferation, angiogenesis, and distant metastasis. This molecular aberration predicts poor prognosis in multiple cancers, including lung, gastric, breast, and hepatic malignancies.

2. PD-1 (CD279)

Programmed cell death protein 1 (PD-1) is an immune checkpoint protein expressed on T and B lymphocytes. It negatively regulates immune cell activity to maintain immune tolerance and prevent autoimmune diseases. However, this physiological mechanism can be hijacked by cancer cells to evade immune surveillance and destruction.

3. PD-L1 (CD274/B7-H1)

Programmed death-ligand 1 (PD-L1) is the primary ligand of PD-1. The binding of PD-L1 to PD-1 transmits inhibitory signals that suppress antigen-specific T-cell proliferation and enhance regulatory T-cell stability, constructing an immunosuppressive tumor microenvironment. High PD-L1 expression is a key predictive marker for lung cancer immunotherapy efficacy.

IHC Detection Methods and Product Applications

Immunohistochemical detection of the above biomarkers relies on high-specificity, high-sensitivity antibodies. ANT BIO PTE. LTD. provides recombinant monoclonal antibodies optimized for IHC testing, ensuring stable, reliable, and reproducible results for basic research and clinical sample analysis.

Related Product Portfolio